Stamboulian D
Fundación del Centro de Estudios Infectológicos (FUNCEI), Buenos Aires, Argentina.
Eur J Clin Microbiol Infect Dis. 1995 Jul;14(7):648-54. doi: 10.1007/BF01690747.
The major cost in the treatment of infective endocarditis (IE) is the length of hospitalization required for the administration of intravenous antibiotics. This can be reduced by substituting shorter regimens and by the introduction of outpatient parenteral antibiotic therapy (OPAT). Careful selection of patients is vital for the success of OPAT in IE. The patients should be hemodynamically stable and without clinical complications. The delivery of OPAT for IE followed a clinical and home-based program involving an endocarditis team whose members included an infectious diseases physician, a microbiologist, a cardiologist and a nurse trained in intravenous techniques. Among the antimicrobial agents used in OPAT of IE, single-agent ceftriaxone for four weeks followed by a short course of amoxicillin or ceftriaxone in combination with an aminoglycoside for two weeks (short course) are effective modes of treatment for streptococcal endocarditis, the most common cause of IE. This treatment is also effective for carefully selected patients with other types of endocarditis, such as those due to the HACEK group (Haemophilus aphrophilus/paraphrophilis, Actinobacillus actinomycetem comitans, Caradiobacterium hominis, Eikenella corrodens and Kingella kingae). Staphylococcus aureus, enterococci and late prosthetic valve endocarditis associated with a streptococcus may also be treated on an outpatient basis after stabilization (approximately 2 weeks). As a result of their need for prolonged treatment periods, these patients are also very good candidates for OPAT. In conclusion, new regimens utilizing ceftriaxone once daily and short-term therapy on a clinical or home basis offer the potential benefits of cheaper safer and more convenient treatment for patients with IE.
感染性心内膜炎(IE)治疗的主要成本是静脉使用抗生素所需的住院时间。通过采用更短疗程的方案以及引入门诊胃肠外抗生素治疗(OPAT),住院时间可以缩短。对于IE患者,仔细挑选患者对于OPAT的成功至关重要。患者应血流动力学稳定且无临床并发症。IE的OPAT实施遵循一项临床及居家项目,该项目涉及一个心内膜炎治疗团队,其成员包括一名传染病医生、一名微生物学家、一名心脏病专家以及一名接受过静脉技术培训的护士。在IE的OPAT中使用的抗菌药物中,单剂量头孢曲松使用四周,随后短期使用阿莫西林或头孢曲松联合一种氨基糖苷类药物使用两周(短疗程),是链球菌性心内膜炎(IE最常见病因)的有效治疗方式。这种治疗方法对于精心挑选的患有其他类型心内膜炎的患者也有效,比如由HACEK菌群(嗜沫/副嗜沫嗜血杆菌、伴放线放线杆菌、人心杆菌、腐蚀埃肯菌和金氏金杆菌)引起的心内膜炎患者。金黄色葡萄球菌、肠球菌以及与链球菌相关的晚期人工瓣膜心内膜炎患者在病情稳定后(约2周)也可进行门诊治疗。由于这些患者需要较长的治疗期,他们也是OPAT的理想人选。总之,每日一次使用头孢曲松以及临床或居家的短期治疗的新方案,为IE患者提供了成本更低、更安全且更便捷的潜在治疗优势。